Phase II Success Positions Ra For Potential Blockbuster Opportunity In Myasthenia Gravis
Executive Summary
Ra hopes to launch a Phase III program for zilucoplan next year, with a goal of bringing an alternative therapy for MG patients into competition with Alexion’s Soliris.
You may also be interested in...
UCB Advances Two-Drug Strategy For Myasthenia Gravis
Successful Phase III data for UCB’s C5 inhibitor zilucoplan adds to a similarly positive Phase III readout for its rozanolixizumab in December, but details are lacking. UCB is the only company with two mechanisms for MG.
Alexion’s Phase III Data Position Ultomiris For Expansion Into Myasthenia Gravis
As its acquisition by AstraZeneca moves toward closure, Alexion plans to file the Soliris follow-on for generalized myasthenia gravis in the US, EU and Japan. But potential competition awaits in the C5 inhibitor and FcRn antagonist classes.
Argenx Builds Presence As Efgartigimod Positive In Pivotal Myasthenia Study
The European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries.